Links for Keyword: Drug Abuse

Follow us on Facebook and Twitter, or subscribe to our mailing list, to receive news updates. Learn more.


Links 1 - 20 of 1490

By Catherine Caruso If you give a mouse a beer, he is going to want a cookie—and another, and another. If you give a person enough beer, she might find herself wolfing down a plate of greasy nachos or some other caloric snack. A study published in January in Nature Communications helps to explain why binge drinking, in both mice and humans, so often leads to binge eating even though alcohol is, itself, high in calories. In the first part of the study, neuroscientists Craig Blomeley and Sarah Cains, both at the Francis Crick Institute Mill Hill Laboratory in London, injected mice with the equivalent of roughly two bottles of wine once a day for three consecutive days, mimicking a weekend of heavy drinking. Sure enough, the inebriated mice ate far more than sober mice in a control group. To figure out why, the researchers then exposed thin-sliced postmortem mouse brains to alcohol and measured the resulting neural activity using fluorescent tags and electrodes. They found that ethanol exposure alters calcium exchange in the cells, causing specialized nerve cells called agouti-related protein (AgRP) neurons to fire more frequently and easily. These neurons normally fire when our body needs calories, and research has shown that activating them artificially will cause mice to chow down even when they are full. The study results suggest that alcohol activates AgRP neurons in the brain, giving drunk mice the munchies. The same is likely true for humans because this brain circuitry has been highly conserved across mammal species, Cains says: “I don't doubt that AgRP neurons are activated in humans, and that's why you see this effect.” © 2017 Scientific American

Related chapters from BP7e: Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology; Chapter 13: Homeostasis: Active Regulation of the Internal Environment
Related chapters from MM:Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology; Chapter 9: Homeostasis: Active Regulation of the Internal Environment
Link ID: 23645 - Posted: 05.22.2017

Laura Beil Even though a sprained ankle rarely needs an opioid, a new study of emergency room patients found that about 7 percent of patients got sent home with a prescription for the potentially addictive painkiller anyway. And the more pills prescribed, the greater the chance the prescription would be refilled, raising concerns about continued use. The research adds to evidence that it’s hard for some people to stop taking the pills even after a brief use. State officials in New Jersey recently enacted a law limiting first-time prescriptions to a five-day supply, and other states should consider similar restrictions, says Kit Delgado, an assistant professor of Emergency Medicine and Epidemiology at the University of Pennsylvania. “The bottom line is that we need to do our best not to expose people to opioids,” Delgado says. “And if we do, start with the smallest quantity possible.” The research was presented May 17 at the Society for Academic Emergency Medicine’s annual meeting in Orlando. Previous research has found that the more opioids such as hydrocodone and oxycodone are prescribed, the more likely patients are to keep taking them. But previous studies have been too broad to account for differences in diagnoses — for instance, whether people who received refills kept taking the drug simply because they still were in pain, Delgado says. He and colleagues limited their study to prescriptions written after ankle sprains to people who had not used an opioid in the previous six months. Usually, those injuries aren’t serious and don’t require opioids. |© Society for Science & the Public 2000 - 2017

Related chapters from BP7e: Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology; Chapter 8: General Principles of Sensory Processing, Touch, and Pain
Related chapters from MM:Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology; Chapter 5: The Sensorimotor System
Link ID: 23638 - Posted: 05.20.2017

Lesley McClurg When her youngest daughter, Naomi, was in middle school, Ellen watched the teen disappear behind a screen. Her once bubbly daughter went from hanging out with a few close friends after school to isolating herself in her room for hours at a time. (NPR has agreed to use only the pair's middle names, to protect the teen's medical privacy.) "She started just lying there, not moving and just being on the phone," says Ellen. "I was at a loss about what to do." Ellen didn't realize it then, but her daughter was sinking into a pattern of behavior that some psychiatrists recognize from their patients who abuse drugs or alcohol. It's a problem, they say, that's akin to an eating disorder or gambling disorder – some consider it a kind of internet addiction. Estimates of how many people are affected vary widely, researchers say, and the problem isn't restricted to kids and teens, though some – especially those who have depression or anxiety disorder — may be particularly vulnerable. Naomi had always been kind of a nerd — a straight-A student who also sang in a competitive choir. But she desperately wanted to be popular, and the cool kids talked a lot about their latest YouTube favorites. "I started trying to watch as many videos as I could so, like, I knew as much as they did," says Naomi. "The second I got out of school, I was checking my phone." That's not unusual behavior for many teens and adults these days. © 2017 npr

Related chapters from BP7e: Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Related chapters from MM:Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Link ID: 23631 - Posted: 05.18.2017

A healthy teenager in the US state of South Carolina died from drinking several highly-caffeinated drinks too quickly, a coroner has ruled. Davis Allen Cripe collapsed at a high school in April after drinking a McDonalds latte, a large Mountain Dew soft drink and an energy drink in just under two hours, Gary Watts said. The 16-year-old died from a "caffeine-induced cardiac event causing a probable arrhythmia". He had no pre-existing heart condition. The teenager weighed 90kg (200 lbs) but would not have been considered morbidly obese, Mr Watts said. "This is not a caffeine overdose," Mr Watts told Reuters news agency. "We're not saying that it was the total amount of caffeine in the system, it was just the way that it was ingested over that short period of time, and the chugging of the energy drink at the end was what the issue was with the cardiac arrhythmia." Caffeine would probably not have been seen as a factor in the teenager's death if witnesses had not been able to tell officials what he had been drinking before his death, the Richland County coroner said. The main witness could not say which brand of energy drink Davis drank but said it was from a container the size of a large soft drink. "We're not trying to speak out totally against caffeine," Mr Watts said. "We believe people need to pay attention to their caffeine intake and how they do it, just as they do with alcohol or cigarettes." The American Academy of Paediatrics (AAP) has warned against children and teenagers consuming energy drinks, saying their ingredients have not been tested on children and "no-one can ensure they are safe". It says they have side-effects including irregular heartbeats and blood pressure changes. © 2017 BBC.

Related chapters from BP7e: Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Related chapters from MM:Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Link ID: 23618 - Posted: 05.16.2017

By Michael Le Page In some cultures, it’s traditional for elders to smoke grass, a practice said to help them pass on tribal knowledge. It turns out that they might just be onto something. Teenagers who toke perform less well on memory and attention tasks while under the influence. But low doses of the active ingredient in cannabis, THC, might have the opposite effect on the elderly, reversing brain ageing and restoring learning and memory – at least according to studies of mice. “We repeated these experiments many times,” says team leader Andreas Zimmer at the University of Bonn, Germany. “It’s a very robust and profound effect.” Zimmer’s team has been studying the mammalian endocannabinoid system, which is involved in balancing out our bodies’ response to stress. THC affects us by mimicking similar molecules in this system, calming us down. The researchers discovered that mice with genetic mutations that stop this endocannabinoid system from working properly age faster than normal mice, and show more cognitive decline. This made Zimmer wonder if stimulating the endocannabinoid system in elderly mice might have the opposite effect. To find out, the team gave young (2-month-old), middle-aged (12-month-old) and elderly (18-month-old) mice a steady dose of THC. The amount they received was too small to give them psychoactive effects. After a month, the team tested the mice’s ability to perform cognitive tasks, such as finding their way around mazes, or recognising other individuals. © Copyright Reed Business Information Ltd.

Related chapters from BP7e: Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology; Chapter 7: Life-Span Development of the Brain and Behavior
Related chapters from MM:Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology; Chapter 13: Memory, Learning, and Development
Link ID: 23593 - Posted: 05.09.2017

By CASEY SCHWARTZ OAKLAND, Calif. — In a packed, cavernous space one weekend late in April, a crowd of thousands was becoming increasingly amped up. Rainbow hair was commonplace, purple silk pants were sighted, and the smell of marijuana drifted in from a designated smoking area nearby. Audience members watched the stage with avid interest, leaping to occasionally shoeless feet to applaud and cheer. This wasn’t Coachella, taking place the same weekend some 500 miles south, or any other music festival, but a five-day convention of the Multidisciplinary Association for Psychedelic Studies (MAPS), its first in four years. Rather than rock stars, scientists from schools like Johns Hopkins and N.Y.U. were the main attraction, bringing evidence to the medical case for psychedelics like psilocybin (the active ingredient in magic mushrooms) to assuage end-of-life anxiety, to help deepen meditation practices, to search for the shared underpinnings of spiritual life, and — in a new study — to explore a possible treatment for severe depression. Paul Austin, 26, of Grand Rapids, Mich., a so-called social entrepreneur who runs a website called The Third Wave devoted to getting out information on psychedelic substances, had come to meet other members of the pro-psychedelic community and share with them his vision for how the next generation must proceed. “A lot of the people who are leading the movement now are 60 or 70 years old, based in academia or research,” Mr. Austin said. “But to catalyze change, you have to speak to people, get to them on an emotional level.” The conference was taking place just over the Bay Bridge from the city that introduced psychedelics to the American imagination in the early 1960s, when LSD was relatively new, legal and regarded by those who used it as a portal to expanded consciousness, a deeper life and an enlightened, humane society. (Cary Grant and other Hollywood stars were among those who experimented with it as part of their psychotherapeutic process.) © 2017 The New York Times Company

Related chapters from BP7e: Chapter 16: Psychopathology: Biological Basis of Behavior Disorders; Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Related chapters from MM:Chapter 12: Psychopathology: The Biology of Behavioral Disorders; Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Link ID: 23589 - Posted: 05.08.2017

Amy Maxmen Psychedelic drugs could soon help people, including soldiers, who suffer from post-traumatic stress disorder with the pain of recalling traumatic memories. Psychologists have occasionally given people psychedelic drugs such as LSD or magic mushrooms to induce altered states, in an attempt to treat mental illness. Today, many of those drugs are illegal, but if clinical trials testing their efficacy yield positive results, a handful could become prescription medicines in the next decade. The furthest along in this process is MDMA — a drug sold illegally as ecstasy or Molly — which is showing promise in the treatment of post-traumatic stress disorder (PTSD). Last week, at the Psychedelic Science 2017 conference in Oakland, California, researchers presented unpublished results from phase II trials involving a total of 107 people diagnosed with PTSD. The trial treatment involved a combination of psychotherapy and MDMA (3,4-methylenedioxymethamphetamine). The US Food and Drug Administration (FDA) reviewed these data in November, which were not released to the public at the time. The agency recommended that the researchers move forward with phase III trials, the final stage before potential approval of the drug. At the conference, researchers affiliated with the non-profit organization that is sponsoring the trials, the Multidisciplinary Association for Psychedelic Studies (MAPS) in Santa Cruz, California, presented some of their latest resutls. They used a cinically validated scale that assesses PTSD symptoms such as frequency of nightmares and anxiety levels. More than one year after two or three sessions of MDMA-assisted therapy, about 67% of participants no longer had the illness, according to that scale. About 23% of the control group — who received psychotherapy and a placebo drug — experienced the same benefit. © 2017 Macmillan Publishers Limited,

Related chapters from BP7e: Chapter 16: Psychopathology: Biological Basis of Behavior Disorders; Chapter 15: Emotions, Aggression, and Stress
Related chapters from MM:Chapter 12: Psychopathology: The Biology of Behavioral Disorders; Chapter 11: Emotions, Aggression, and Stress
Link ID: 23554 - Posted: 04.29.2017

By Abigail Beall You can’t eat, you can’t sleep and all you can think about is your next fix. You may be addicted to love. Intense romance can often come with symptoms resembling addiction – euphoria, craving, dependence, withdrawal and relapse – and brain scans have shown that it can be linked to drug-addiction-like activity in the brain’s reward centres. But the idea that people can be addicted to love is contentious. “It gets complicated because people disagree on the correct theory of addiction, and people especially disagree about what we mean when we use the term ‘love’ ”, says Brian Earp, at the Oxford University Centre for Neuroethics. “I think it is when you realise you do not want to be in love yet cannot avoid it, and it causes bad things, like abuse, that we cross the line into something addiction-like,” says Anders Sandberg, also at the Oxford University Centre for Neuroethics. Now Earp and his team have found evidence that there are in fact two different types of love addiction, after reviewing 64 studies of love and addiction published between 1956 and 2016. They found that people who feel desperately alone when not in a relationship, and try to replace an ex-partner straight away, could have what the team has called a “narrow” form of love addiction.

Related chapters from BP7e: Chapter 12: Sex: Evolutionary, Hormonal, and Neural Bases; Chapter 5: Hormones and the Brain
Related chapters from MM:Chapter 8: Hormones and Sex; Chapter 8: Hormones and Sex
Link ID: 23552 - Posted: 04.29.2017

Austin Frakt The burden of substance abuse disorders can fall heavily on the families and friends of those who battle addictions. But society also pays a great deal through increased crime. Treatment programs can reduce those costs. For at least two decades, we’ve known substance use and crime go hand in hand. More than half of violent offenders and one-third of property offenders say they committed crimes while under the influence of alcohol or drugs. Researchers with the Centers for Disease Control and Prevention recently estimated that prescription opioid abuse, dependence and overdoses cost the public sector $23 billion a year, with a third of that attributable to crime. An additional $55 billion per year reflects private-sector costs attributable to productivity losses and health care expenses. About 80,000 Americans are incarcerated for opioid-related crimes alone. The total annual economic burden of all substance use disorders — not just those involving opioids — is in the hundreds of billions of dollars. In an editorial accompanying the C.D.C. researchers’ study, Harold Pollack, co-director of the University of Chicago Crime Lab, wrote that opioid-associated crime, like all crime, extracts an even larger toll when you consider its impact on families and communities. “The most important reason to support treatment is to improve the well-being and social function of people with addiction disorders,” Mr. Pollack said. But there are other social benefits. When the criminally active get help for this, “the economic value of crime reduction largely or totally offsets the costs of treatment,” he added. Relative to the costs of crime alone, treatment for substance use disorders is a good deal. Even though a typical burglary may result in a few thousand dollars of tangible losses, researchers have estimated that people are willing to pay 10 times that amount to avoid that loss and 100 times more to avoid armed robbery. This reflects the fact that crime exacts a large psychological toll — the threat or climate of it is far more costly than the crimes themselves. © 2017 The New York Times Company

Related chapters from BP7e: Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Related chapters from MM:Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Link ID: 23527 - Posted: 04.24.2017

Ian Sample Science editor Brain scans have revealed the first evidence for what appears to be a heightened state of consciousness in people who took psychedelic drugs in the name of science. Healthy volunteers who received LSD, ketamine or psilocybin, a compound found in magic mushrooms, were found to have more random brain activity than normal while under the influence, according to a study into the effects of the drugs. The shift in brain activity accompanied a host of peculiar sensations that the participants said ranged from floating and finding inner peace, to distortions in time and a conviction that the self was disintegrating. Researchers at the University of Sussex and Imperial College, London, measured the activity of neurons in people’s brains as the drugs took hold. Similar measurements have shown that when people are asleep or under anaesthetic, their neurons tend to fire in a more predictable way than when they are awake. “What we find is that under each of these psychedelic compounds, this specific measure of global conscious level goes up, so it moves in the other direction. The neural activity becomes more unpredictable,” said Anil Seth, a professor of neuroscience at the University of Sussex. “Until now, we’ve only ever seen decreases compared to the baseline of the normal waking state.”

Related chapters from BP7e: Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology; Chapter 16: Psychopathology: Biological Basis of Behavior Disorders
Related chapters from MM:Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology; Chapter 12: Psychopathology: The Biology of Behavioral Disorders
Link ID: 23511 - Posted: 04.19.2017

Lauren Frayer Gandelina Damião, 78, is permanently hunched, carrying her sorrow. She lost three children to heroin in the 1990s. A quarter century ago, her cobblestone lane, up a grassy hill from Lisbon's Tagus River, was littered with syringes. She recalls having to search for her teenagers in graffitied stone buildings nearby, where they would shoot up. "It was a huge blow," Damião says, pointing to framed photos on her wall of Paulo, Miguel and Liliana. "I was a good mother. I never gave them money for drugs. But I couldn't save them." For much of the 20th century, Portugal was a closed, Catholic society, with a military dictator and no drug education. In the early 1970s, young Portuguese men were drafted to fight wars in the country's African colonies, where many were exposed to drugs for the first time. Some came home addicted. In 1974, there was a revolution — and an explosion of freedom. "It was a little bit like the Americans in Vietnam. Whiskey was cheaper than water, and cannabis was easy to access. So people came home from war with some [drug] habits," says João Goulão, Portugal's drug czar. "Suddenly everything was different [after the revolution]. Freedom! And drugs were something that came with that freedom. But we were completely naive." By the 1990s, 1 percent of Portugal's population was hooked on heroin. It was one of the worst drug epidemics in the world, and it prompted Portugal's government to take a novel approach: It decriminalized all drugs. Starting in 2001, possession or use of any drug — even heroin — has been treated as a health issue, not a crime. © 2017 npr

Related chapters from BP7e: Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Related chapters from MM:Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Link ID: 23506 - Posted: 04.19.2017

Smoking causes one in 10 deaths worldwide, a new study shows, half of them in just four countries - China, India, the US and Russia. Despite decades of tobacco control policies, population growth has seen an increased number of smokers, it warned. Researchers said mortality could rise further as tobacco companies aggressively targeted new markets, especially in the developing world. The report was published in the medical journal The Lancet. "Despite more than half a century of unequivocal evidence of the harmful effects of tobacco on health, today, one in every four men in the world is a daily smoker," said senior author Dr Emmanuela Gakidou. "Smoking remains the second largest risk factor for early death and disability, and so to further reduce its impact we must intensify tobacco control to further reduce smoking prevalence and attributable burden." The Global Burden of Diseases report was based on smoking habits in 195 countries and territories between 1990 and 2015. It found that nearly one billion people smoked daily in 2015 - one in four men and one in 20 women. That was a reduction from one in three men and one in 12 women who lit up in 1990. However, population growth meant there was an increase in the overall number of smokers, up from 870 million in 1990. © 2017 BBC

Related chapters from BP7e: Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Related chapters from MM:Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Link ID: 23453 - Posted: 04.06.2017

By CHRISTOPHER J. FERGUSON and PATRICK MARKEY Is video game addiction a real thing? It’s certainly common to hear parents complain that their children are “addicted” to video games. Some researchers even claim that these games are comparable to illegal drugs in terms of their influence on the brain — that they are “digital heroin” (the neuroscientist Peter C. Whybrow) or “digital pharmakeia” (the neuroscientist Andrew Doan). The American Psychiatric Association has identified internet gaming disorder as a possible psychiatric illness, and the World Health Organization has proposed including “gaming disorder” in its catalog of mental diseases, along with drug and alcohol addiction. This is all terribly misguided. Playing video games is not addictive in any meaningful sense. It is normal behavior that, while perhaps in many cases a waste of time, is not damaging or disruptive of lives in the way drug or alcohol use can be. Let’s start with the neuroscientific analogy: that the areas in the brain associated with the pleasures of drug use are the same as those associated with the pleasures of playing video games. This is true but not illuminating. These areas of the brain — those that produce and respond to the neurotransmitter dopamine — are involved in just about any pleasurable activity: having sex, enjoying a nice conversation, eating good food, reading a book, using methamphetamines. The amount of dopamine involved in these activities, however, differs widely. Playing a video game or watching an amusing video on the internet causes roughly about as much dopamine to be released in your brain as eating a slice of pizza. By contrast, using a drug like methamphetamine can cause a level of dopamine release 10 times that or more. On its own, the fact that a pleasurable activity involves dopamine release tells us nothing else about it. © 2017 The New York Times Company

Related chapters from BP7e: Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Related chapters from MM:Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Link ID: 23441 - Posted: 04.04.2017

By MATT RICHTEL LOS ANGELES — Nine days after Nikolas Michaud’s latest heroin relapse, the skinny 27-year-old sat on a roof deck at a new drug rehabilitation clinic here. He picked up a bong, filled it with a pinch of marijuana, lit the leaves and inhaled. All this took place in plain view of the clinic’s director. “The rules here are a little lax,” Mr. Michaud said. In almost any other rehab setting in the country, smoking pot would be a major infraction and a likely cause for being booted out. But here at High Sobriety — the clinic with a name that sounds like the title of a Cheech and Chong comeback movie — it is not just permitted, but part of the treatment. The new clinic is experimenting with a concept made possible by the growing legalization of marijuana: that pot, rather than being a gateway into drugs, could be a gateway out. A small but growing number of pain doctors and addiction specialists are overseeing the use of marijuana as a substitute for more potent and dangerous drugs. Dr. Mark Wallace, chairman of the division of pain medicine in the department of anesthesia at the University of California, San Diego, said over the last five years he has used marijuana to help several hundred patients transition off opiates. “The majority of patients continue to use it,” he said of marijuana. But he added that they tell him of the opiates: “I feel like I was a slave to that drug. I feel like I have my life back.” Dr. Wallace is quick to note that his evidence is anecdotal and more study is needed. Research in rats, he said, supports the idea that the use of cannabinoids can induce withdrawal from heavier substances. But in humans? © 2017 The New York Times Company

Related chapters from BP7e: Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Related chapters from MM:Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Link ID: 23415 - Posted: 03.28.2017

By THOMAS FULLER SANTA ROSA, Calif. — In the heart of Northern California’s wine country, a civil engineer turned marijuana entrepreneur is adding a new dimension to the art of matching fine wines with gourmet food: cannabis and wine pairing dinners. Sam Edwards, co-founder of the Sonoma Cannabis Company, charges diners $100 to $150 for a meal that experiments with everything from marijuana-leaf pesto sauce to sniffs of cannabis flowers paired with sips of a crisp Russian River chardonnay. “It accentuates the intensity of your palate,” Mr. Edwards, 30, said of the dinners, one of which was held recently at a winery with sweeping views of the Sonoma vineyards. “We are seeing what works and what flavors are coming out.” Sonoma County, known to the world for its wines, is these days a seedbed of cannabis experimentation. The approval of recreational cannabis use by California voters in November has spurred local officials here to embrace the pot industry and the tax income it may bring. “We’re making this happen,” said Julie Combs, a member of the Santa Rosa City Council, who is helping lead an effort to issue permits to cannabis companies. “This is an industry that can really help our region.” Of the many ways in which California is on a collision course with the Trump administration, from immigration to the environment, the state’s enthusiastic embrace of legalized and regulated marijuana may be one of the biggest tests of the federal government’s power. Attorney General Jeff Sessions has equated marijuana with heroin and, on Wednesday, mentioned cannabis in the context of the “scourge of drug abuse.” © 2017 The New York Times Compan

Related chapters from BP7e: Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology; Chapter 8: General Principles of Sensory Processing, Touch, and Pain
Related chapters from MM:Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology; Chapter 5: The Sensorimotor System
Link ID: 23379 - Posted: 03.20.2017

Doctors who limit the supply of opioids they prescribe to three days or less may help patients avoid the dangers of dependence and addiction, a new study suggests. Among patients without cancer, a single day's supply of a narcotic painkiller can result in 6 per cent of patients being on an opioid a year later, the researchers said. The odds of long-term opioid use increased most sharply in the first days of therapy, particularly after five days of taking the drugs. The rate of long-term opioid use increased to about 13 per cent for patients who first took the drugs for eight days or more, according to the report. "Awareness among prescribers, pharmacists and persons managing pharmacy benefits that authorization of a second opioid prescription doubles the risk for opioid use one year later might deter overprescribing of opioids," said senior researcher Martin Bradley. He is from the division of pharmaceutical evaluation and policy at the University of Arkansas for Medical Sciences. "The chances of long-term opioid use, use that lasts one year or more, start increasing with each additional day supplied, starting after the third day, and increase substantially after someone is prescribed five or more days, and especially after someone is prescribed one month of opioid therapy," Bradley said. The odds of chronic opioid use also increase when a second prescription is given or refilled, he noted. ©2017 CBC/Radio-Canada.

Related chapters from BP7e: Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology; Chapter 8: General Principles of Sensory Processing, Touch, and Pain
Related chapters from MM:Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology; Chapter 5: The Sensorimotor System
Link ID: 23373 - Posted: 03.19.2017

By MATT RICHTEL Amid an opioid epidemic, the rise of deadly synthetic drugs and the widening legalization of marijuana, a curious bright spot has emerged in the youth drug culture: American teenagers are growing less likely to try or regularly use drugs, including alcohol. With minor fits and starts, the trend has been building for a decade, with no clear understanding as to why. Some experts theorize that falling cigarette-smoking rates are cutting into a key gateway to drugs, or that antidrug education campaigns, long a largely failed enterprise, have finally taken hold. But researchers are starting to ponder an intriguing question: Are teenagers using drugs less in part because they are constantly stimulated and entertained by their computers and phones? The possibility is worth exploring, they say, because use of smartphones and tablets has exploded over the same period that drug use has declined. This correlation does not mean that one phenomenon is causing the other, but scientists say interactive media appears to play to similar impulses as drug experimentation, including sensation-seeking and the desire for independence. Or it might be that gadgets simply absorb a lot of time that could be used for other pursuits, including partying. Nora Volkow, director of the National Institute on Drug Abuse, says she plans to begin research on the topic in the next few months, and will convene a group of scholars in April to discuss it. The possibility that smartphones were contributing to a decline in drug use by teenagers, Dr. Volkow said, was the first question she asked when she saw the agency’s most recent survey results. The survey, “Monitoring the Future,” an annual government-funded report measuring drug use by teenagers, found that past-year use of illicit drugs other than marijuana was at the lowest level in the 40-year history of the project for eighth, 10th and 12th graders. © 2017 The New York Times Company

Related chapters from BP7e: Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Related chapters from MM:Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Link ID: 23357 - Posted: 03.15.2017

Ian Sample Science editor Selling high calorie foods in plain packaging could help in the battle against obesity according to a leading researcher who has won a share of the most lucrative prize in neuroscience for his work on the brain’s reward system. The colourful wrapping and attractive advertising of calorie-rich foods encourage people to buy items that put them at risk of overeating and becoming obese in the future, said Wolfram Schultz, a professor of neuroscience at the University of Cambridge. “We should not advertise, propagate or encourage the unnecessary ingestion of calories,” Schultz said at a press conference held on Monday to announce the winners of the 2017 Brain Prize. “There should be some way of regulating the desire to get more calories. We don’t need these calories.” “Colourful wrapping of high energy foods of course makes you buy more of that stuff and once you have it in your fridge, it’s in front of you every time you open the fridge and ultimately you’re going to eat it and eat too much,” he added. Schultz shares the €1m prize from the Lundbeck Foundation in Denmark with professors Peter Dayan, director of the Gatsby Computational Neuroscience Unit at UCL, and Ray Dolan, director of the Max Planck UCL Centre for Computational Psychiatry and Ageing. Together, the scientists unravelled how the brain uses rewards to learn and shape behaviour.

Related chapters from BP7e: Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology; Chapter 13: Homeostasis: Active Regulation of the Internal Environment
Related chapters from MM:Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology; Chapter 9: Homeostasis: Active Regulation of the Internal Environment
Link ID: 23320 - Posted: 03.06.2017

By Alistair Steele, CBC News The opioid crisis that's claiming lives across the country has taken a particularly sinister turn in the nation's capital. Or so it appears. Much of the public discussion — and a good deal of the news coverage — surrounding the growing number of deaths by opioid overdose in Ottawa has concentrated on the cruel toll the drugs are taking on the city's teenagers, particularly those living in the western suburb of Kanata. The fake prescription pills they take recreationally are cheap and easy to find, but they can also be laced with potentially lethal doses of fentanyl. This tragic trend was given a fresh, young face when Grade 9 student Chloe Kotval, just 14, died from an overdose on Valentine's Day. Police later confirmed pills found near the girl's body contained fentanyl. In a statement released the day of their daughter's funeral, Kotval's parents wrote: "We are concerned about the epidemic nature of the use of high-grade pharmaceuticals amongst young people and their lack of knowledge about them — the consequences of using them are real and terrible." While families have every right to be concerned and to prepare for the worst, there's no evidence showing young people are any more susceptible to opioid overdoses than any other group of drug users in Ottawa. Sean O'Leary, whose own teenage daughter became addicted to counterfeit percocets, told CBC about coming home one night to find a 17-year-old boy who had overdosed in his garage. ©2017 CBC/Radio-Canada.

Related chapters from BP7e: Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology; Chapter 8: General Principles of Sensory Processing, Touch, and Pain
Related chapters from MM:Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology; Chapter 5: The Sensorimotor System
Link ID: 23312 - Posted: 03.04.2017

Recently, an international team of researchers reported that the cerebellum may play a previously unforeseen role in brain alterations associated with the addictive consumption of drugs. Until now, the cerebellum—which has historically been viewed by most neuroscientists as primarily the seat of fine-tuned motor control and coordination—has gone under the radar of drug addiction specialists. The latest reports linking the cerebellum and drug addiction were based on a broad range of groundbreaking research published over the past two years. These findings were recently compiled and featured in two different journals: Neuroscience & Biobehavioral Reviews and the Journal of Neuroscience. Bringing all of this research together was the brainchild of Marta Miquel, professor in the research group Addiction and Neuroplasticity at the Universitat Jaume I (UJI) in Spain. Miguel spearheaded her own original research as well as the initiative to collect multidisciplinary research from a broad spectrum of international institutions and to present these cerebellar findings cohesively under one umbrella. (Cerebellar is the sister word to cerebral and means “relating to or located in the cerebellum.”) In addition to the UJI team, contributing research for this compilation of studies on the cerebellum and addiction came from the University of Cambridge and University of Leeds (United Kingdom); University of Turin (Italy); Universidad Veracruzana (Mexico); the University of Kentucky, Washington State University, and McLean Hospital Translational Neuroscience Laboratory and Mailman Research Center (USA). Psychology Today © 1991-2017 Sussex Publishers, LLC

Related chapters from BP7e: Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Related chapters from MM:Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Link ID: 23301 - Posted: 03.02.2017